ES2761266T3 - Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada - Google Patents

Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada Download PDF

Info

Publication number: ES2761266T3
Authority: ES; Spain
Prior art keywords: expression; patients; patient; determined; survival time
Prior art date: 2015-11-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES16793890T

Other languages

English (en)

Spanish (es)

Inventor

Richard Moreau

Emmanuel Weiss

Pierre-Emmanuel Rautou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Assistance Publique Hopitaux de Paris APHP

Institut National de la Sante et de la Recherche Medicale INSERM

Universite Paris Descartes

Universite Paris Diderot Paris 7

Original Assignee

Assistance Publique Hopitaux de Paris APHP

Institut National de la Sante et de la Recherche Medicale INSERM

Universite Paris Descartes

Universite Paris Diderot Paris 7

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-10

Filing date

2016-11-09

Publication date

2020-05-19

2016-11-09 Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes, Universite Paris Diderot Paris 7 filed Critical Assistance Publique Hopitaux de Paris APHP

2020-05-19 Application granted granted Critical

2020-05-19 Publication of ES2761266T3 publication Critical patent/ES2761266T3/es

Status Active legal-status Critical Current

2036-11-09 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims abstract description 39
230000004083 survival effect Effects 0.000 title claims abstract description 32
206010009208 Cirrhosis alcoholic Diseases 0.000 title claims abstract description 25
208000010002 alcoholic liver cirrhosis Diseases 0.000 title claims abstract description 25
230000014509 gene expression Effects 0.000 claims abstract description 86
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 60
102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 claims abstract description 19
101150056224 MX2 gene Proteins 0.000 claims abstract 2
101150058616 Oas2 gene Proteins 0.000 claims abstract 2
108090000623 proteins and genes Proteins 0.000 claims description 80
101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 claims description 17
102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims description 14
101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 claims description 11
GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims description 9
102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 9
102100034597 E3 ubiquitin-protein ligase TRIM22 Human genes 0.000 claims description 9
101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 9
101000848629 Homo sapiens E3 ubiquitin-protein ligase TRIM22 Proteins 0.000 claims description 9
101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 9
102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 9
102100028538 Guanylate-binding protein 4 Human genes 0.000 claims description 8
101001058851 Homo sapiens Guanylate-binding protein 4 Proteins 0.000 claims description 8
102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims description 8
108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 claims description 7
238000003757 reverse transcription PCR Methods 0.000 claims description 4
239000002131 composite material Substances 0.000 claims 1
239000000523 sample Substances 0.000 description 58
150000007523 nucleic acids Chemical group 0.000 description 23
206010016654 Fibrosis Diseases 0.000 description 22
230000007882 cirrhosis Effects 0.000 description 22
208000019425 cirrhosis of liver Diseases 0.000 description 22
230000034994 death Effects 0.000 description 22
231100000517 death Toxicity 0.000 description 22
210000004027 cell Anatomy 0.000 description 20
102000039446 nucleic acids Human genes 0.000 description 20
108020004707 nucleic acids Proteins 0.000 description 20
238000013139 quantization Methods 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 11
238000009396 hybridization Methods 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
210000001616 monocyte Anatomy 0.000 description 11
108010050904 Interferons Proteins 0.000 description 10
238000005516 engineering process Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
102000014150 Interferons Human genes 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000000203 mixture Substances 0.000 description 9
239000004054 semiconductor nanocrystal Substances 0.000 description 9
238000002054 transplantation Methods 0.000 description 9
238000011529 RT qPCR Methods 0.000 description 7
230000006698 induction Effects 0.000 description 7
229940079322 interferon Drugs 0.000 description 7
238000004393 prognosis Methods 0.000 description 7
230000035945 sensitivity Effects 0.000 description 7
102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
230000003321 amplification Effects 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
230000006870 function Effects 0.000 description 6
210000002865 immune cell Anatomy 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
239000000758 substrate Substances 0.000 description 6
108010012236 Chemokines Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 description 5
102100029607 Interferon-induced protein 44 Human genes 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 5
239000011521 glass Substances 0.000 description 5
238000002955 isolation Methods 0.000 description 5
238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
206010003445 Ascites Diseases 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 4
101000952078 Homo sapiens Probable ATP-dependent RNA helicase DDX60 Proteins 0.000 description 4
102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 4
108020004711 Nucleic Acid Probes Proteins 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
102100037439 Probable ATP-dependent RNA helicase DDX60 Human genes 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
230000027455 binding Effects 0.000 description 4
239000000090 biomarker Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000002853 nucleic acid probe Substances 0.000 description 4
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000007473 univariate analysis Methods 0.000 description 4
101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 3
102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 3
102000019034 Chemokines Human genes 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 3
101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 3
101001082063 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 5 Proteins 0.000 description 3
102100036981 Interferon regulatory factor 1 Human genes 0.000 description 3
102100027356 Interferon-induced protein with tetratricopeptide repeats 5 Human genes 0.000 description 3
208000034486 Multi-organ failure Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000007969 cellular immunity Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000000975 dye Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
208000030304 gastrointestinal bleeding Diseases 0.000 description 3
RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
239000003446 ligand Substances 0.000 description 3
208000019423 liver disease Diseases 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000000178 monomer Substances 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000010837 poor prognosis Methods 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
238000011002 quantification Methods 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 description 2
101710159080 Aconitate hydratase A Proteins 0.000 description 2
101710159078 Aconitate hydratase B Proteins 0.000 description 2
208000033237 Aicardi-Goutières syndrome Diseases 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
208000014644 Brain disease Diseases 0.000 description 2
-1 Brilliant Yellow Chemical compound 0.000 description 2
102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 2
238000000018 DNA microarray Methods 0.000 description 2
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 2
102000007260 Deoxyribonuclease I Human genes 0.000 description 2
108010008532 Deoxyribonuclease I Proteins 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000032274 Encephalopathy Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
206010019728 Hepatitis alcoholic Diseases 0.000 description 2
101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 2
101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 2
101000998500 Homo sapiens Interferon-induced 35 kDa protein Proteins 0.000 description 2
101001103771 Homo sapiens Ribonuclease H2 subunit A Proteins 0.000 description 2
101001103768 Homo sapiens Ribonuclease H2 subunit B Proteins 0.000 description 2
101000670585 Homo sapiens Ribonuclease H2 subunit C Proteins 0.000 description 2
101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
102100033273 Interferon-induced 35 kDa protein Human genes 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
108091005685 RIG-I-like receptors Proteins 0.000 description 2
238000002123 RNA extraction Methods 0.000 description 2
102000044126 RNA-Binding Proteins Human genes 0.000 description 2
101710105008 RNA-binding protein Proteins 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
102100039493 Ribonuclease H2 subunit A Human genes 0.000 description 2
102100039474 Ribonuclease H2 subunit B Human genes 0.000 description 2
102100039610 Ribonuclease H2 subunit C Human genes 0.000 description 2
108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 2
101150114242 SAMHD1 gene Proteins 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
208000002353 alcoholic hepatitis Diseases 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000011237 bivariate analysis Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 2
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000005291 magnetic effect Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000004853 protein function Effects 0.000 description 2
239000002096 quantum dot Substances 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
229940043267 rhodamine b Drugs 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
DUFUXAHBRPMOFG-UHFFFAOYSA-N 1-(4-anilinonaphthalen-1-yl)pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C1=CC=CC=C11)=CC=C1NC1=CC=CC=C1 DUFUXAHBRPMOFG-UHFFFAOYSA-N 0.000 description 1
ZTTARJIAPRWUHH-UHFFFAOYSA-N 1-isothiocyanatoacridine Chemical compound C1=CC=C2C=C3C(N=C=S)=CC=CC3=NC2=C1 ZTTARJIAPRWUHH-UHFFFAOYSA-N 0.000 description 1
108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 1
102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 1
VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 1
102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
SMBSZJBWYCGCJP-UHFFFAOYSA-N 3-(diethylamino)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(N(CC)CC)=CC2=C1 SMBSZJBWYCGCJP-UHFFFAOYSA-N 0.000 description 1
YJCCSLGGODRWKK-NSCUHMNNSA-N 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulphonic acid Chemical compound OS(=O)(=O)C1=CC(NC(=O)C)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YJCCSLGGODRWKK-NSCUHMNNSA-N 0.000 description 1
SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
ZWONWYNZSWOYQC-UHFFFAOYSA-N 5-benzamido-3-[[5-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C(N=NC2=CC(NC3=NC(NC4=CC=C(C=C4)S(O)(=O)=O)=NC(Cl)=N3)=CC=C2S(O)(=O)=O)C(=CC2=C1C(NC(=O)C1=CC=CC=C1)=CC(=C2)S(O)(=O)=O)S(O)(=O)=O ZWONWYNZSWOYQC-UHFFFAOYSA-N 0.000 description 1
AXGKYURDYTXCAG-UHFFFAOYSA-N 5-isothiocyanato-2-[2-(4-isothiocyanato-2-sulfophenyl)ethyl]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1CCC1=CC=C(N=C=S)C=C1S(O)(=O)=O AXGKYURDYTXCAG-UHFFFAOYSA-N 0.000 description 1
HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
TXSWURLNYUQATR-UHFFFAOYSA-N 6-amino-2-(3-ethenylsulfonylphenyl)-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1C1=CC=CC(S(=O)(=O)C=C)=C1 TXSWURLNYUQATR-UHFFFAOYSA-N 0.000 description 1
WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
YALJZNKPECPZAS-UHFFFAOYSA-N 7-(diethylamino)-3-(4-isothiocyanatophenyl)-4-methylchromen-2-one Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C1=CC=C(N=C=S)C=C1 YALJZNKPECPZAS-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
208000022309 Alcoholic Liver disease Diseases 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
102100021661 Aryl hydrocarbon receptor nuclear translocator-like protein 2 Human genes 0.000 description 1
FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010070545 Bacterial translocation Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010057573 Chronic hepatic failure Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000010334 End Stage Liver Disease Diseases 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 1
101000896221 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 2 Proteins 0.000 description 1
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 1
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 description 1
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108091058560 IL8 Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108010014726 Interferon Type I Proteins 0.000 description 1
102000002227 Interferon Type I Human genes 0.000 description 1
102100039065 Interleukin-1 beta Human genes 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102100036701 Interleukin-12 subunit beta Human genes 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
102000017578 LAG3 Human genes 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
101001011385 Mus musculus Interferon regulatory factor 1 Proteins 0.000 description 1
101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
108090000944 RNA Helicases Proteins 0.000 description 1
102000004409 RNA Helicases Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
229910052771 Terbium Inorganic materials 0.000 description 1
101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
102100024324 Toll-like receptor 3 Human genes 0.000 description 1
102100039360 Toll-like receptor 4 Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000012152 algorithmic method Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000012491 analyte Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
230000007375 bacterial translocation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000011444 chronic liver failure Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000004665 defense response Effects 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
XHXYXYGSUXANME-UHFFFAOYSA-N eosin 5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 XHXYXYGSUXANME-UHFFFAOYSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
239000004174 erythrosine Substances 0.000 description 1
229940011411 erythrosine Drugs 0.000 description 1
235000012732 erythrosine Nutrition 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
201000011200 hepatorenal syndrome Diseases 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229940107698 malachite green Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
238000000491 multivariate analysis Methods 0.000 description 1
239000002159 nanocrystal Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000000123 paper Substances 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
108010089193 pattern recognition receptors Proteins 0.000 description 1
102000007863 pattern recognition receptors Human genes 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
239000013615 primer Substances 0.000 description 1
239000002987 primer (paints) Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
AJMSJNPWXJCWOK-UHFFFAOYSA-N pyren-1-yl butanoate Chemical compound C1=C2C(OC(=O)CCC)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 AJMSJNPWXJCWOK-UHFFFAOYSA-N 0.000 description 1
150000003220 pyrenes Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
230000016259 regulation of nucleocytoplasmic transport Effects 0.000 description 1
TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
VLCQZHSMCYCDJL-UHFFFAOYSA-N tribenuron methyl Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)N(C)C1=NC(C)=NC(OC)=N1 VLCQZHSMCYCDJL-UHFFFAOYSA-N 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
238000012795 verification Methods 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pathology (AREA)
Immunology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

ES16793890T 2015-11-10 2016-11-09 Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada Active ES2761266T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP15306785		2015-11-10
PCT/EP2016/077129 WO2017081073A1 (fr)	2015-11-10	2016-11-09	Procédés pour prévoir la durée de survie de patients atteints d'une cirrhose alcoolique décompensée

Publications (1)

Publication Number	Publication Date
ES2761266T3 true ES2761266T3 (es)	2020-05-19

Family

ID=54548121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES16793890T Active ES2761266T3 (es)	2015-11-10	2016-11-09	Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada

Country Status (4)

Country	Link
US (1)	US10793909B2 (fr)
EP (1)	EP3374518B1 (fr)
ES (1)	ES2761266T3 (fr)
WO (1)	WO2017081073A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4774339A (en)	1987-08-10	1988-09-27	Molecular Probes, Inc.	Chemically reactive dipyrrometheneboron difluoride dyes
US5132432A (en)	1989-09-22	1992-07-21	Molecular Probes, Inc.	Chemically reactive pyrenyloxy sulfonic acid dyes
US5274113A (en)	1991-11-01	1993-12-28	Molecular Probes, Inc.	Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en)	1994-05-20	1995-07-18	Molecular Probes, Inc.	Dibenzopyrrometheneboron difluoride dyes
US5248782A (en)	1990-12-18	1993-09-28	Molecular Probes, Inc.	Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en)	1991-02-13	1994-08-16	Molecular Probes, Inc.	Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5187288A (en)	1991-05-22	1993-02-16	Molecular Probes, Inc.	Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5262357A (en)	1991-11-22	1993-11-16	The Regents Of The University Of California	Low temperature thin films formed from nanocrystal precursors
US5505928A (en)	1991-11-22	1996-04-09	The Regents Of University Of California	Preparation of III-V semiconductor nanocrystals
US6048616A (en)	1993-04-21	2000-04-11	Philips Electronics N.A. Corp.	Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US7625697B2 (en) *	1994-06-17	2009-12-01	The Board Of Trustees Of The Leland Stanford Junior University	Methods for constructing subarrays and subarrays made thereby
US5571018A (en)	1994-11-23	1996-11-05	Motorola, Inc.	Arrangement for simulating indirect fire in combat training
US5690807A (en)	1995-08-03	1997-11-25	Massachusetts Institute Of Technology	Method for producing semiconductor particles
US5800996A (en)	1996-05-03	1998-09-01	The Perkin Elmer Corporation	Energy transfer dyes with enchanced fluorescence
US5696157A (en)	1996-11-15	1997-12-09	Molecular Probes, Inc.	Sulfonated derivatives of 7-aminocoumarin
US5830912A (en)	1996-11-15	1998-11-03	Molecular Probes, Inc.	Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5866366A (en)	1997-07-01	1999-02-02	Smithkline Beecham Corporation	gidB
US6130101A (en)	1997-09-23	2000-10-10	Molecular Probes, Inc.	Sulfonated xanthene derivatives
US6322901B1 (en)	1997-11-13	2001-11-27	Massachusetts Institute Of Technology	Highly luminescent color-selective nano-crystalline materials
US5990479A (en)	1997-11-25	1999-11-23	Regents Of The University Of California	Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en)	1997-11-25	2001-03-27	The Regents Of The University Of California	Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6617583B1 (en)	1998-09-18	2003-09-09	Massachusetts Institute Of Technology	Inventory control
US6114038A (en)	1998-11-10	2000-09-05	Biocrystal Ltd.	Functionalized nanocrystals and their use in detection systems
US6855202B2 (en)	2001-11-30	2005-02-15	The Regents Of The University Of California	Shaped nanocrystal particles and methods for making the same
CA2373146A1 (fr)	1999-05-07	2000-11-16	Quantum Dot Corporation	Procede de detection d'une substance a analyser au moyen de nanocristaux semiconducteurs
US6225198B1 (en)	2000-02-04	2001-05-01	The Regents Of The University Of California	Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6306736B1 (en)	2000-02-04	2001-10-23	The Regents Of The University Of California	Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
AU2001250937A1 (en)	2000-03-22	2001-10-03	Quantum Dot Corporation	Loop probe hybridization assay for polynucleotide analysis
WO2001091808A2 (fr)	2000-06-01	2001-12-06	The Board Of Regents For Oklahoma State University	Bioconjugues de nanoparticules en tant que produits radiopharmaceutiques
CA2417816A1 (fr)	2000-08-04	2002-02-14	Molecular Probes, Inc.	Derives de 1,2-dihydro-7-hydroxyquinolines contenant des noyaux fusionnes
US6649138B2 (en)	2000-10-13	2003-11-18	Quantum Dot Corporation	Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en)	2000-12-28	2002-07-04	Zehnder Donald A.	Flow synthesis of quantum dot nanocrystals
US6709929B2 (en)	2001-06-25	2004-03-23	North Carolina State University	Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
CA2453450A1 (fr)	2001-07-20	2003-11-06	Quantum Dot Corporation	Nanoparticules luminescentes et techniques de preparation
GB0617581D0 (en) *	2006-09-07	2006-10-18	Ucl Business Plc	Biomarkers for assessing liver function

2016
- 2016-11-09 WO PCT/EP2016/077129 patent/WO2017081073A1/fr not_active Ceased
- 2016-11-09 EP EP16793890.1A patent/EP3374518B1/fr active Active
- 2016-11-09 US US15/775,092 patent/US10793909B2/en active Active
- 2016-11-09 ES ES16793890T patent/ES2761266T3/es active Active

Also Published As

Publication number	Publication date
US10793909B2 (en)	2020-10-06
EP3374518A1 (fr)	2018-09-19
US20180320232A1 (en)	2018-11-08
WO2017081073A1 (fr)	2017-05-18
EP3374518B1 (fr)	2019-11-06

Publication	Publication Date	Title
US20230045305A1 (en)	2023-02-09	Rna determinants for distinguishing between bacterial and viral infections
US11884978B2 (en)	2024-01-30	Pathogen biomarkers and uses therefor
CN107075569B (zh)	2022-01-07	用于诊断结核病的生物标记物及其组合
AU2015213486A9 (en)	2016-07-07	Biomarker signature method, and apparatus and kits therefor
AU2017315328A1 (en)	2019-03-21	Systemic inflammatory and pathogen biomarkers and uses therefor
US12385926B2 (en)	2025-08-12	MMP-8 as a marker for identifying infectious disease
WO2007100913A2 (fr)	2007-09-07	Gènes exprimés de façon différentielle dans les troubles bipolaires et/ou dans la schizophrénie
CN107208159A (zh)	2017-09-26	宿主dna作为克罗恩氏病的生物标记物
IL285031A (en)	2023-02-01	Diagnosis of inflammatory bowel diseases
US20250236913A1 (en)	2025-07-24	New method to diagnose inflammatory diseases
US20180305761A1 (en)	2018-10-25	METHODS AND KITS FOR PREDICTION AND DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS (hCMV) CONGENITAL TRANSMISSION
WO2022125702A1 (fr)	2022-06-16	Analyse de l'expression d'un gène hôte pour le diagnostic d'une infection par le coronavirus à syndrome respiratoire aigu sévère 2
Yang et al.	2022	Evaluation of IFIT3 and ORM1 as biomarkers for discriminating active tuberculosis from latent infection
ES2761266T3 (es)	2020-05-19	Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada
US20180321242A1 (en)	2018-11-08	Viral biomarkers and uses therefor
WO2022153323A1 (fr)	2022-07-21	Marqueurs pour diagnostiquer des infections
US20170029896A1 (en)	2017-02-02	Prognostic kits, arrays compositions and methods for predicting interferon treatment efficacy in a subject
WO2013173266A1 (fr)	2013-11-21	Procédés d'identification de motifs d'expression induits par ifn et utilisation dans le diagnostic, la surveillance et la thérapie
KR20200084435A (ko)	2020-07-13	신장이식 환자의 급성거부반응 진단용 miRNA 바이오 마커 및 이의 용도
WO2025027127A1 (fr)	2025-02-06	Nouvelle méthode de pronostic d'insuffisance rénale
Afshar et al.	2021	Current and emerging technologies for the diagnosis of sars-cov-2
Hughes et al.	2022	Evaluation of the Disease, Sample Collection and Diagnostics
US20230135802A1 (en)	2023-05-04	Methods for diagnosis and in vitro risk stratification for head and neck cancer based on exosomal mrnas
CN120064667A (zh)	2025-05-30	一种结核病分子标志物组合及其用途
WO2022136252A1 (fr)	2022-06-30	Méthodes de pronostic de la réponse humorale d'un sujet avant une vaccination